Eterna Therapeutics Inc. financial data

Symbol
ERNA on Nasdaq
Industry
Pharmaceutical Preparations
Location
1035 Cambridge Street, Suite 18 A, Cambridge, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Brooklyn ImmunoTherapeutics, Inc. (to 10/14/2022), NTN BUZZTIME INC (to 3/23/2021), NTN COMMUNICATIONS INC (to 12/20/2005)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 78.6 % -45.5%
Debt-to-equity -3.32K % -1559%
Return On Equity 1.56K %
Return On Assets -48.4 % +41.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.41M shares +0.01%
Common Stock, Shares, Outstanding 5.41M shares +0.02%
Entity Public Float 9.7M USD -59.2%
Common Stock, Value, Issued 27K USD 0%
Weighted Average Number of Shares Outstanding, Basic 5.41M shares +2.02%
Weighted Average Number of Shares Outstanding, Diluted 5.41M shares +2.02%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 47K USD
Cost of Revenue 95K USD
Research and Development Expense 1.69M USD -69%
General and Administrative Expense 16.6M USD +35.1%
Operating Income (Loss) -22M USD +4.01%
Nonoperating Income (Expense) -1.94M USD -257%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -23.9M USD -10.4%
Income Tax Expense (Benefit) -5K USD -109%
Net Income (Loss) Attributable to Parent -23.9M USD -10.1%
Earnings Per Share, Basic -4.42 USD/shares +16.8%
Earnings Per Share, Diluted -4.42 USD/shares +16.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.59M USD +40.8%
Assets, Current 3.58M USD -7.92%
Property, Plant and Equipment, Net 654K USD +239%
Operating Lease, Right-of-Use Asset 36M USD +1.79%
Goodwill 2.04M USD 0%
Other Assets, Noncurrent 120K USD -91.3%
Assets 46.5M USD -1%
Accounts Payable, Current 2.19M USD -18%
Employee-related Liabilities, Current 134K USD -58.6%
Accrued Liabilities, Current 2.39M USD +13.3%
Liabilities, Current 9.6M USD +34%
Operating Lease, Liability, Noncurrent 36M USD +3.09%
Other Liabilities, Noncurrent 84K USD
Liabilities 55M USD +27.7%
Retained Earnings (Accumulated Deficit) -199M USD -13.7%
Stockholders' Equity Attributable to Parent -8.53M USD -321%
Liabilities and Equity 46.5M USD -1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.75M USD +38.1%
Net Cash Provided by (Used in) Financing Activities 1.39M USD
Net Cash Provided by (Used in) Investing Activities -97K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 5.41M shares +0.02%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.68M USD +12.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 18.3M USD +13.3%
Deferred Tax Assets, Gross 29.3M USD +76.9%
Operating Lease, Liability 40.3M USD +14.7%
Payments to Acquire Property, Plant, and Equipment 101K USD
Lessee, Operating Lease, Liability, to be Paid 64.2M USD -2.43%
Property, Plant and Equipment, Gross 607K USD +126%
Operating Lease, Liability, Current 4.27M USD +2366%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.24M USD +2.85%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.08M USD +2.43%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure -15.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 23.9M USD -22.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.31M USD +1.3%
Preferred Stock, Shares Issued 156K shares 0%
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 393K USD +225%
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.41M USD +1.72%
Additional Paid in Capital 191M USD +6.45%
Preferred Stock, Shares Outstanding 156K shares 0%
Depreciation, Depletion and Amortization 39K USD +85.7%
Deferred Tax Assets, Net of Valuation Allowance 11M USD +2673%
Share-based Payment Arrangement, Expense 1.04M USD -41.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%